698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Abstract
Effective therapies are critically needed for previously treated patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC), particularly those considered hard-to-treat with poor prognostic factors. In the phase III EV-301 trial (NCT03474107), EV showed superior overall survival (OS) compared with standard chemotherapy (SC) in pts with previously treated la/mUC; this subgroup analysis evaluates the efficacy and safety of EV...
Paper Details
Title
698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Published Date
Sep 1, 2021
Journal
Volume
32
Pages
S710 - S711
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History